![]() |
Name |
Erythroglaucin
|
Molecular Formula | C16H12O6 | |
IUPAC Name* |
1,4,5-trihydroxy-7-methoxy-2-methylanthracene-9,10-dione
|
|
SMILES |
CC1=CC(=C2C(=C1O)C(=O)C3=C(C2=O)C(=CC(=C3)OC)O)O
|
|
InChI |
InChI=1S/C16H12O6/c1-6-3-9(17)12-13(14(6)19)15(20)8-4-7(22-2)5-10(18)11(8)16(12)21/h3-5,17-19H,1-2H3
|
|
InChIKey |
VUUONEBXXLQCQX-UHFFFAOYSA-N
|
|
Synonyms |
Erythroglaucin; Erythroglaucine; 476-57-3; 1,4,5-trihydroxy-7-methoxy-2-methylanthracene-9,10-dione; CHEBI:68790; ANTHRAQUINONE, 7-METHOXY-2-METHYL-1,4,5-TRIHYDROXY-; 9,10-Anthracenedione, 1,4,5-trihydroxy-7-methoxy-2-methyl-; CCRIS 6424; BRN 1890890; Erythroglaucine_120099; CHEMBL463597; SCHEMBL16226462; DTXSID30197215; Q27137181; 1,4,5-Trihydroxy-7-methoxy-2-methylanthra-9,10-quinone #
|
|
CAS | 476-57-3 | |
PubChem CID | 10152 | |
ChEMBL ID | CHEMBL463597 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 300.26 | ALogp: | 3.2 |
HBD: | 3 | HBA: | 6 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 104.0 | Aromatic Rings: | 3 |
Heavy Atoms: | 22 | QED Weighted: | 0.597 |
Caco-2 Permeability: | -5.104 | MDCK Permeability: | 0.00001190 |
Pgp-inhibitor: | 0.264 | Pgp-substrate: | 0 |
Human Intestinal Absorption (HIA): | 0.267 | 20% Bioavailability (F20%): | 0.017 |
30% Bioavailability (F30%): | 0.991 |
Blood-Brain-Barrier Penetration (BBB): | 0.004 | Plasma Protein Binding (PPB): | 97.27% |
Volume Distribution (VD): | 0.412 | Fu: | 4.43% |
CYP1A2-inhibitor: | 0.965 | CYP1A2-substrate: | 0.762 |
CYP2C19-inhibitor: | 0.151 | CYP2C19-substrate: | 0.067 |
CYP2C9-inhibitor: | 0.679 | CYP2C9-substrate: | 0.65 |
CYP2D6-inhibitor: | 0.479 | CYP2D6-substrate: | 0.232 |
CYP3A4-inhibitor: | 0.341 | CYP3A4-substrate: | 0.093 |
Clearance (CL): | 6.549 | Half-life (T1/2): | 0.566 |
hERG Blockers: | 0.012 | Human Hepatotoxicity (H-HT): | 0.207 |
Drug-inuced Liver Injury (DILI): | 0.919 | AMES Toxicity: | 0.785 |
Rat Oral Acute Toxicity: | 0.538 | Maximum Recommended Daily Dose: | 0.942 |
Skin Sensitization: | 0.922 | Carcinogencity: | 0.699 |
Eye Corrosion: | 0.011 | Eye Irritation: | 0.946 |
Respiratory Toxicity: | 0.383 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC000335 | ![]() |
0.769 | D07MGA | ![]() |
0.333 | ||
ENC000966 | ![]() |
0.761 | D01XWG | ![]() |
0.306 | ||
ENC000362 | ![]() |
0.681 | D07VLY | ![]() |
0.299 | ||
ENC000930 | ![]() |
0.657 | D0C9XJ | ![]() |
0.299 | ||
ENC005227 | ![]() |
0.657 | D0K8KX | ![]() |
0.293 | ||
ENC001497 | ![]() |
0.630 | D06GCK | ![]() |
0.293 | ||
ENC002229 | ![]() |
0.610 | D0N1FS | ![]() |
0.282 | ||
ENC002766 | ![]() |
0.595 | D04AIT | ![]() |
0.272 | ||
ENC005280 | ![]() |
0.593 | D01XDL | ![]() |
0.266 | ||
ENC002089 | ![]() |
0.562 | D0AZ8C | ![]() |
0.266 |